Final answer:
In the case presented, due to the increased serum growth hormone and decreased IGF-1 levels, it is likely that the hepatocytes contain decreased phosphorylated quantities of growth hormone receptor tyrosine.
Step-by-step explanation:
The patient described likely has an altered response to growth hormone (GH) due to a disruption in the GH signaling pathway. GH exerts its effects directly and indirectly, with the indirect effects mediated by insulin-like growth factor-1 (IGF-1) which is a growth-promoting protein produced by the liver.
Normally, GH binds to its receptor on the hepatocyte cell surface, causing receptor tyrosine phosphorylation, which then triggers a cascade of intracellular events leading to the production of IGF-1. If serum IGF-1 levels are low despite elevated levels of GH, this suggests a problem in the GH pathway at the liver, specifically in the GH receptor signal transduction leading to IGF-1 production. Therefore, the hepatocytes most likely contain decreased phosphorylated quantities of growth hormone receptor tyrosine (option C).